Aurinia Pharmaceuticals (AUPH) Assets Average (2017 - 2026)

Aurinia Pharmaceuticals (AUPH) has 9 years of Assets Average data on file, last reported at $737.8 million in Q1 2026.

• Quarterly Assets Average rose 39.8% year-over-year to $737.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $737.8 million (up 39.8% YoY) and the FY2025 annual result came in at $651.1 million, up 18.52% from the prior year.
• Assets Average climbed to $737.8 million in Q1 2026, from $639.6 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $737.8 million in Q1 2026 to a low of $461.3 million in Q1 2023.
• A 5-year average of $536.0 million and a median of $525.1 million in 2022 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2023 — Assets Average dropped 12.15% — and 2026, when it surged 39.8%.
• Tracing AUPH's Assets Average over 5 years: stood at $479.6 million in 2022, then grew by 15.01% to $551.5 million in 2023, then slipped by 0.28% to $550.0 million in 2024, then increased by 16.28% to $639.6 million in 2025, then gained by 15.36% to $737.8 million in 2026.
• The last three Assets Average figures came in at $737.8 million (Q1 2026), $639.6 million (Q4 2025), and $515.0 million (Q3 2025), per Business Quant data.